Atossa Therapeutics Moves Forward in Breast Cancer Treatment After FDA Meeting

Atossa Therapeutics Advances Breast Cancer Treatment with FDA Insights

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in innovative breast cancer therapies, achieves a critical milestone by completing a Type C meeting with the U.S. Food and Drug Administration (FDA) on November 17, 2025. This meeting focuses on regulatory strategies for (Z)-endoxifen, a promising compound in the company’s pipeline. The FDA provides Atossa with essential feedback on potential expedited regulatory pathways, which could facilitate the advancement of (Z)-endoxifen in various treatment settings, including metastatic breast cancer (mBC), neoadjuvant therapy, and risk reduction for breast cancer. This guidance marks an important step forward in Atossa’s commitment to improving patient outcomes and streamlining the development of its therapeutic solutions.

Atossa's President and CEO, Steven Quay, underscores the significance of this interaction with the FDA, noting that it clarifies routes to accelerate clinical development and regulatory review processes for (Z)-endoxifen. With a focus on delivering effective treatments, Atossa is currently preparing for a dose-ranging study targeting mBC and is actively enrolling participants in the Phase 2 EVANGELINE trial, which investigates neoadjuvant therapy for estrogen receptor-positive and HER2-negative breast cancer. Additionally, the company is pursuing a low-dose strategy aimed at reducing breast cancer risk associated with high mammographic density, demonstrating its comprehensive approach to addressing breast cancer at multiple stages.

As part of its strategic development plan, Atossa has submitted an Investigational New Drug (IND) application for its mBC program and intends to file additional INDs in 2026 for combination therapies beyond monotherapy. Senior VP of Research and Development, Janet Rea, emphasizes the structured nature of Atossa’s clinical program, which aims for decisive milestones and has already completed several trials involving nearly 800 participants. The company is optimistic that the combination of its foundational work on (Z)-endoxifen and the insights gained from the FDA will pave the way towards achieving multiple regulatory endpoints, thus positioning Atossa as a leader in the field of breast cancer treatment and prevention.

In addition to its clinical advancements, Atossa remains committed to fostering innovation within the biopharmaceutical industry. The company’s proactive engagement with regulatory bodies like the FDA demonstrates its dedication to transparency and collaboration in the drug development process. As Atossa Therapeutics continues to refine its strategies and expand its clinical pipeline, it is poised to make significant contributions to the ongoing fight against breast cancer, ultimately striving to enhance the quality of care for patients worldwide.

With its robust development framework and ongoing commitment to clinical excellence, Atossa Therapeutics is setting a strong foundation for future breakthroughs in breast cancer therapies, positioning itself as a vital player in the biopharmaceutical landscape.